ThromboGenics and BioInvent Win “Licensing Deal of the Year” at the Scrip Awards 2009

Strategic partnership with Roche for novel anti-cancer antibody TB-403 (anti-PIGF) recognised in award

20-Nov-2009 - Sweden

ThromboGenics NV and BioInvent International announce that they won “Licensing Deal of the Year” at the Scrip Awards 2009. The award recognises the major partnership deal that ThromboGenics and BioInvent signed with Roche for their novel anti-cancer monoclonal antibody TB-403 (anti-PIGF). It acknowledges the achievement of both companies in crafting a licensing deal that has both monetary and strategic benefits to all parties. The Scrip Awards are one of the biotech and pharmaceutical industry’s most prestigious and highly contested international awards, and they are chosen by a panel of senior executives from the biotech and pharma industry.

Under the terms of the deal with Roche, ThromboGenics and its co-development partner BioInvent received an upfront payment of €50 million, with an additional €450 million in potential milestones, as well as double digit royalties on future product sales. The working relationship with Roche is continuing to progress well and recently ThromboGenics and BioInvent announced positive results in a Phase Ib trial of TB-403 in patients with advanced solid tumours. The results showed positive safety and tolerability data. ThromboGenics, who discovered TB-403, receives 60% and BioInvent 40% of all revenue from the deal.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances